{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:12:52Z","timestamp":1790748772099,"version":"4.1.0"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"19","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neurofibromatosis type 2 (NF2) is a dominantly inherited cancer disorder caused by mutations at the NF2 gene locus. Merlin, the protein product of the NF2 gene, has been shown to negatively regulate Rac1 signaling by inhibiting its downstream effector kinases, the p21-activated kinases (Pak). Given the implication of Paks in tumorigenesis, it is plausible that merlin's tumor suppressive function might be mediated, at least in part, via inhibition of the Paks. We present data indicating this is indeed the case. First, analysis of primary schwannoma samples derived from NF2 patients showed that in a significant fraction of the tumors, the activity of Pak1 was highly elevated. Second, we used shRNAs to knockdown Pak1, 2, and 3 in NIH3T3 cells expressing a dominant-negative form of merlin, NF2BBA (NIH3T3\/NF2BBA), and find that simultaneous knockdown of Pak1-3 in these cells significantly reduced their growth rates in vitro and inhibited their ability to form tumors in vivo. Finally, while attempting to silence Pak1 in rat schwannoma cells, we found that these cells were unable to tolerate long-term Pak1 inhibition and rapidly moved to restore Pak1 levels by shutting down Pak1 shRNA expression through a methylation-dependent mechanism. These data suggest that inhibiting Pak could be a beneficial approach for the development of therapeutics toward NF2. In addition, the finding that the shRNA-mediated Pak1 suppression was silenced rapidly by methylation raises questions about the future application of such technologies for the treatment of diseases such as cancer. [Cancer Res 2008;68(19):7932\u20137]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-0866","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:53:23Z","timestamp":1222822403000},"page":"7932-7937","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Validation of the p21-Activated Kinases as Targets for Inhibition in Neurofibromatosis Type 2"],"prefix":"10.1158","volume":"68","author":[{"given":"Chunling","family":"Yi","sequence":"first","affiliation":[{"name":"1Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik W.","family":"Wilker","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Yaffe","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Stemmer-Rachamimov","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Kissil","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,9,30]]},"reference":[{"key":"2022061700265543800_B1","doi-asserted-by":"crossref","unstructured":"Yohay KH. The genetic and molecular pathogenesis of NF1 and NF2. Semin Pediatr Neurol\u20082006; 13: 21\u20136.","DOI":"10.1016\/j.spen.2006.01.007"},{"key":"2022061700265543800_B2","doi-asserted-by":"crossref","unstructured":"Kissil JL, Johnson KC, Eckman MS, Jacks T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem\u20082002; 277: 10394\u20139.","DOI":"10.1074\/jbc.M200083200"},{"key":"2022061700265543800_B3","doi-asserted-by":"crossref","unstructured":"Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac\/Cdc42 signaling to merlin. J Biol Chem\u20082002; 277: 883\u20136.","DOI":"10.1074\/jbc.C100553200"},{"key":"2022061700265543800_B4","doi-asserted-by":"crossref","unstructured":"Alfthan K, Heiska L, Gronholm M, Renkema GH, Carpen O. Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem\u20082004; 279: 18559\u201366.","DOI":"10.1074\/jbc.M313916200"},{"key":"2022061700265543800_B5","doi-asserted-by":"crossref","unstructured":"Jin H, Sperka T, Herrlich P, Morrison H. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature\u20082006; 442: 576\u20139.","DOI":"10.1038\/nature04856"},{"key":"2022061700265543800_B6","doi-asserted-by":"crossref","unstructured":"Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell\u20082001; 1: 63\u201372.","DOI":"10.1016\/S1534-5807(01)00009-0"},{"key":"2022061700265543800_B7","doi-asserted-by":"crossref","unstructured":"Xiao GH, Gallagher R, Shetler J, et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol\u20082005; 25: 2384\u201394.","DOI":"10.1128\/MCB.25.6.2384-2394.2005"},{"key":"2022061700265543800_B8","doi-asserted-by":"crossref","unstructured":"Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO. Upregulation of the Rac1\/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet\u20082003; 12: 1211\u201321.","DOI":"10.1093\/hmg\/ddg146"},{"key":"2022061700265543800_B9","doi-asserted-by":"crossref","unstructured":"Nakai Y, Zheng Y, MacCollin M, Ratner N. Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells. J Neurosci\u20082006; 26: 3390\u20135.","DOI":"10.1523\/JNEUROSCI.4865-05.2006"},{"key":"2022061700265543800_B10","doi-asserted-by":"crossref","unstructured":"Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell\u20082003; 12: 841\u20139.","DOI":"10.1016\/S1097-2765(03)00382-4"},{"key":"2022061700265543800_B11","doi-asserted-by":"crossref","unstructured":"Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P. Merlin\/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res\u20082007; 67: 520\u20137.","DOI":"10.1158\/0008-5472.CAN-06-1608"},{"key":"2022061700265543800_B12","doi-asserted-by":"crossref","unstructured":"Hirokawa Y, Tikoo A, Huynh J, et al. A clue to the therapy of neurofibromatosis type 2: NF2\/merlin is a PAK1 inhibitor. Cancer J\u20082004; 10: 20\u20136.","DOI":"10.1097\/00130404-200401000-00006"},{"key":"2022061700265543800_B13","doi-asserted-by":"crossref","unstructured":"Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet\u20082003; 33: 401\u20136.","DOI":"10.1038\/ng1117"},{"key":"2022061700265543800_B14","doi-asserted-by":"crossref","unstructured":"Buchwald G, Hostinova E, Rudolph MG, et al. Conformational switch and role of phosphorylation in PAK activation. Mol Cell Biol\u20082001; 21: 5179\u201389.","DOI":"10.1128\/MCB.21.15.5179-5189.2001"},{"key":"2022061700265543800_B15","unstructured":"Chong C, Tan L, Lim L, Manser E. The mechanism of PAK activation: auto-phosphorylation events in both regulatory and kinase domains control activity. J Biol Chem\u20082001; 22: 22."},{"key":"2022061700265543800_B16","doi-asserted-by":"crossref","unstructured":"Johnson KC, Kissil JL, Fry JL, Jacks T. Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene\u20082002; 21: 5990\u20137.","DOI":"10.1038\/sj.onc.1205693"},{"key":"2022061700265543800_B17","doi-asserted-by":"crossref","unstructured":"Tang Y, Chen Z, Ambrose D, et al. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol\u20081997; 17: 4454\u201364.","DOI":"10.1128\/MCB.17.8.4454"},{"key":"2022061700265543800_B18","doi-asserted-by":"crossref","unstructured":"Vadlamudi RK, Adam L, Wang RA, et al. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem\u20082000; 275: 36238\u201344.","DOI":"10.1074\/jbc.M002138200"},{"key":"2022061700265543800_B19","doi-asserted-by":"crossref","unstructured":"Howe AK, Juliano RL. Regulation of anchorage-dependent signal transduction by protein kinase A and p21-activated kinase. Nat Cell Biol\u20082000; 2: 593\u2013600.","DOI":"10.1038\/35023536"},{"key":"2022061700265543800_B20","doi-asserted-by":"crossref","unstructured":"Lu PY XF, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet\u20082005; 54: 117\u201342.","DOI":"10.1016\/S0065-2660(05)54006-9"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/19\/7932\/2597295\/7932.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/19\/7932\/2597295\/7932.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:43:08Z","timestamp":1655426588000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/19\/7932\/541435\/Validation-of-the-p21-Activated-Kinases-as-Targets"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,30]]},"references-count":20,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2008,9,30]]},"published-print":{"date-parts":[[2008,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-0866","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22375535","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375535.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375529.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375526","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375529","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375526.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375532.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375532","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6497858","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497858.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,30]]}}}